Application of Bronchoscopy Biopsy Combined with ROSE in Lung Cancer Screening in Patients with COPD

FU Yanhong; DING Jing; XIA Kui; SUN Wei

doi:10.3639/i.issn.2095-3097.2024.10.010

Abstract：Objective To explore the role of bronchoscopy biopsy combined with rapid on-site evaluation(ROSE)technology in lung cancer screening in patients with chronic obstructive pulmonary disease(COPD).Methods A retrospective study.A total of 80 patients with COPD and lung cancer admitted to our hospital from May 2022 to May 2024 were selected.The patients were divided into observation group(bronchoscopy biopsy±ROSE)and control group(bronchoscopy biopsy)according to whether combined with ROSE technology,40 cases in each group.Compare the qualification rate of samples submitted for examination and the diagnosis of the first biopsy,the number of forceps taken,the operation time,the amount of bleeding,and the occurrence of complications between the two groups of patients.Results The qualified rate of samples submitted for inspection and the first biopsy diagnosis rate of the observation group were 97.50％(39/40)and 92.50％(37/40),respectively,which were both higher than those of the control group[82.50％(33/40)and 72.50％(29/40)](P＜0.05).The number of clamps and operation time in the observation group[(6.87±1.52)times,(33.59±4.21)min]were greater than those in the control group[(5.63±0.79)times,(31.72±3.86)min](P＜0.05).There was no statistically significant difference in bleeding volume between the two groups[(4.23±0.69)ml vs(4.48±0.82)ml](P＞0.05).There was no statistically significant difference in the incidence of complications between the two groups(P＞0.05).Conclusion The application of bronchoscopy biopsy combined with ROSE technology in patients with COPD and lung cancer can improve the sample qualification rate and the first biopsy diagnosis rate.It is safe and feasible.